With respect to new treatment technologies, emergency stenting has been shown by Sigwart and colleagues to be a potential way of restoring coronary blood flow using the self-expanding stainless-steel Wallstent8 and by Roubin and associates9 using a coil design. In these patient studies, stent placement has led to a dramatic improvement in angiographic appearance of complex, propagated coronary dissection. Similarly, Spears et al10 have shown that laser balloon angioplasty may be effective in managing abrupt closure. Experimental studies performed by these investigators have suggested a "welding"-like effect of neodinium-YAG laser energy harnessed in this fashion. In 76 of 90 patients (84%), laser balloon angioplasty improved angiographic appearance, restored coronary blood flow, stabilized the patient, and prevented the need for emergency bypass surgery.'0 Alternative less-expensive energy sources that achieve a similar heat-sealing effect, such as radiofrequency, are being pursued.
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Although directional atherectomy has been used to manage abrupt closure,4 a recent case report by Serruys"1 documents coronary artery perforation in this setting and raises caution about application of this particular technology to "salvage" balloon angioplasty. Despite this incident, the outlook for new device reduction of abrupt closure and its attendant serious complications is promising and deserves further study.
Expansion to Complex Anatomical Subsets
As an extension to more control or frank avoidance of abrupt closure, the new devices may permit a wider application for transcatheter approaches. Pa 20 2) the use of a dual-balloon catheter to transfer genes to a porcine artery, 21 3) endovascular drug delivery via a porous balloon,22 4) impregnation of stents with heparin or other pharmacological agents, and 5) the use of biodegradable polymers that have the capacity to "pave" or "seal" the intima23 or serve as a reservoir for sustained release of a particular drug. Thus, many very specific, targeted approaches for the diseased vessel wall might be achieved without systemic pharmacological intervention. Vehicles such as stents or debulking with atherectomy may serve as pivotal steps requisite for effective endovascular drug delivery or, ultimately, gene transfer.
Pitfalls New Complications
An aftermath of the new coronary artery procedures has been the emergence of a new set of complications. Examples of such complications include 1) coronary artery perforation that has occurred with laser angioplasty and the atherectomy procedures11"'3"17; 2) subacute thrombosis days after stent placement with all of the stents so far tested, with or without apparent adequate anticoagulation2J'8; and 3) the "no reflow" phenomenon after the high-speed drilling and emulsification process of rotational angioplasty,24 which presumably is related to distal showering of microparticles. Each of these is extremely serious, can lead to death or myocardial infarction, and represents new complications that are rarely if ever reported with the use of balloon angioplasty. 25 Refinements in technique and operator experience may reduce the risk of such dreaded complications. Guidance systems such as intravascular ultrasound or angioscopy may be incorporated into the atherectomy procedure to avoid removal of the media or adventitia vessel wall components. Fluorescence spectroscopy during laser treatment has the potential to direct plaque ablation. Alternatively, intraprocedural techniques such as frozen section of tissue retrieved from atherectomy may indicate the level of resection and avoid unnecessary deep injury. It is already clear that atherectomy is capable of media and advential resection in a significant proportion of patients and that although not typically accompanied by immediate complication,26 deeper penetration appears to increase the risk of restenosis. 17 Similarly, the predisposition for stents to develop thrombosis has led to a very intensive polypharmaceutical regimen that includes preprocedural aspirin, dipyridamole and dextran, intraprocedural heparin (and urokinase for one stent8), and postoperative coumadin, aspirin, and dipyridamole. The unexpected thrombosis of a stent days to a week after successful placement is fortunately unusual and may be avoided by newer stents coated with heparin, hirudin, or other thrombin or antiplatelet inhibitors.
With the no-reflow phenomenon after rotational angioplasty, a progressive increase in burr size rather than the initial use of a large burr may prevent the accretion of larger particulate matter and the sequelae of embolization. Integration with a technique such as vacuuming or filtering, which actually removes the particles or debris rather than relying on microemulsification, represents another alternative for avoidance of this complication.
Economic Impact
A generally unanticipated offshoot from the new devices will be a significant economic problem at various levels. Already there has been considerable charge to the investigators for use of the devices and support equipment. Currently, the charge to the investigator for a single directional atherectomy catheter setup is more than $1,500, which includes the specialized guiding catheter, motor drive unit, and guide wire. The current stent charges range from $400 to $1,500 per device, and there is an incremental 2-3-day hospitalization period required to achieve adequate anticoagulation. These "single" catheter or devices charges are relatively small compared with those of the laser console and power source, which has cost between $100,000 and $300,000 to institutions performing laser system investigation.
The current policy of the Food and Drug Administration (FDA) device bureau is to allow the manufacturer to charge the investigator up to and including the anticipated approved and marketed price.27 This permits manufacturers, often small companies relying on venture capital, to charge considerable amounts for device use while the procedure is truly investigational, and has no safety or efficacy profile.
The justification response from various manufacturers has been that there is a significant cost of device preparation and that there are a multitude of alternative investigators if one is not prepared to defray such expenses. These charges cannot be billed to the patient or third-party payor as there are strict guidelines against charging patients for investigational equipment or for the procedure itself. In some instances, like stenting, even the cardiac catheterization and preparatory angioplasty have been disallowed by third-party payors because of the association with an investigational device. For the active clinical investigator interested in pursuing this important area of research, a financial catch-22 situation is quite apparent: It is quite expensive to do the research, and there is no support mechanism.
These charges represent only those incurred during the investigational phase of device development; the anticipated costs after commercial approval will undoubtedly have a much larger impact. The Tied closely with the training problem are the overall lack of perspective and the anticipated operator exuberance. An example of this situation is the recent trend in balloon valvuloplasty, particularly for the aortic valve. Initial reports of relatively small numbers of patients confirmed feasibility and overall safety of aortic valvuloplasty.32 Enthusiasm led to overuse until adequate data in literally thousands of patients suggested that aortic valvuloplasty was accompanied by an excessive risk of restenosis in the first year after the procedure.33 With limited numbers of patients and, particularly noteworthy, limited follow-up (i.e., more than 6 months with coronary angiography), the hard facts about the new devices may become evident only after commercialization.
There are several latent motivating factors for such operator exuberance: the charm feature of a technique quite distinct from balloon angioplasty, the feeling of competition or inadequacy among operators not engaged in new procedures, the perceived need of each operator to maximize experience, the potential ability to use the new devices as a marketing ploy for patient referrals, and direct revenue or earnings based on performance of a highly specialized procedure. There has already been concern expressed in the medical literature about misdirected use of the new devices.34,35 Industry Marketing
With the restricted number of investigational sites that can evaluate each device, the supply-to-demand ratio highly favors the position of the manufacturers. Several issues have arisen representing an outgrowth of this imbalance situation. First, the ability to capitalize, even in the premarketing phase of nearly every device, has led to substantial equipment charges to the investigator. Second, equipment manufacturers have at times used their position as a wedge to sell conventional balloon equipment in cases in which both prototypic and routine catheters are coupled. Examples are the restriction of clinical sites of a project to only those using the manufacturer's ordi- each strategy may be proven beneficial for a patient subset, such that each device will have a niche. Another level of complexity in clinical research within this field will be to define the appropriate use of different technologies that can be used for the same indication. For example, a comparison of stenting versus laser balloon angioplasty for abrupt closure needs scrutiny in future trials. For patients at high risk, integration with the new support devices, including percutaneous cardiopulmonary bypass, catheter-mounted left ventricular assist device, or retroperfusion, will need sorting out. Novel approaches to chronic total occlusion constitute another group of devices that are in the early phase of development.3940 The number of combinations and permutations of all the new devices is clearly formidable. Without question, the new device era for coronary revascularization is an exhilarating one with prodigious capacity for growth and application in the future. Maintaining an awareness of the multiplicity of problems and deficiencies will hopefully facilitate meaningful progress in this vital field.
